Know Cancer

or
forgot password

Regulatory Post Marketing Surveillance Study on Nexavar®


N/A
N/A
N/A
Open (Enrolling)
Both
Carcinoma, Hepatocellular, Carcinoma, Renal Cell

Thank you

Trial Information

Regulatory Post Marketing Surveillance Study on Nexavar®


Inclusion Criteria:



- Patients with diagnosis of advanced Renal Cell Carcinoma and Hepatocellular carcinoma
and decision taken by the physician to prescribe Nexavar

Exclusion Criteria:

- Hypersensitivity to the active substances or any of gradient of the study drug
ingredients (according to the local product information)

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Adverse events collection

Outcome Time Frame:

From start of treatment to 4 weeks after discontinuation of treatment

Safety Issue:

Yes

Principal Investigator

Bayer Study Director

Investigator Role:

Study Director

Investigator Affiliation:

Bayer

Authority:

South Korea: Korea Food and Drug Administration (KFDA)

Study ID:

14792

NCT ID:

NCT01012011

Start Date:

October 2009

Completion Date:

December 2014

Related Keywords:

  • Carcinoma, Hepatocellular
  • Carcinoma, Renal Cell
  • Carcinoma, Hepatocellular
  • Carcinoma, Renal Cell
  • Carcinoma
  • Carcinoma, Renal Cell
  • Carcinoma, Hepatocellular

Name

Location